Denali Therapeutics Inc’s recent filing unveils that its Director Krognes Steve E. unloaded Company’s shares for reported $1.9 million on Apr 01 ’24. In the deal valued at $20.50 per share,92,500 shares were sold. As a result of this transaction, Krognes Steve E. now holds 47,341 shares worth roughly $0.86 million.
Then, SATO VICKI L sold 1,666 shares, generating $33,487 in total proceeds. Upon selling the shares at $20.10, the Director now owns 119,709 shares.
Before that, SATO VICKI L sold 1,666 shares. Denali Therapeutics Inc shares valued at $30,604 were divested by the Director at a price of $18.37 per share. As a result of the transaction, SATO VICKI L now holds 121,375 shares, worth roughly $2.22 million.
Citigroup initiated its Denali Therapeutics Inc [DNLI] rating to a Buy in a research note published on December 13, 2023; the price target was $32. B. Riley Securities started covering the stock on September 06, 2023. It rated DNLI as “a Buy”.
Price Performance Review of DNLI
On Friday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock fall -4.75% to $18.26. Over the last five days, the stock has lost -5.83%. Denali Therapeutics Inc shares have fallen nearly -14.91% since the year began. Nevertheless, the stocks have fallen -24.33% over the past one year. While a 52-week high of $33.31 was reached on 02/27/24, a 52-week low of $15.45 was recorded on 02/05/24. SMA at 50 days reached $19.12, while 200 days put it at $21.37. A total of 1.1 million shares were traded, compared to the trading of 0.87 million shares in the previous session.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 17.73, which if violated will result in even more drops to 17.20. On the upside, there is a resistance level at 18.90. A further resistance level may holdings at 19.54. The Relative Strength Index (RSI) on the 14-day chart is 41.96, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.89, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.88%. Stochastics %K at 20.34% indicates the stock is a holding.
The most recent change occurred on January 30, 2023 when SVB Securities began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
